Eram Mukhtar Husain

Dr. Eram Mukhtar Husain


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Metabolites
Verified
Journal Article
Open access
PDF file
RMRashid Mir
Rashid Mir
SAShrooq Ali Albarqi
Shrooq Ali Albarqi
WAWed Abdullah Albalawi
Wed Abdullah Albalawi
HAHanan E. Alatwi
Hanan E. Alatwi
MAMarfat Alatawy
Marfat Alatawy
SBShabnam Bashir
Shabnam Bashir
Background: The human digestive system contains approximately 100 trillion bacteria. The gut microbiota is an emerging field of research that is associated with specific biological processes in many diseases, including cardiovascular disease, obesity, diabetes, brain disease, rheumatoid arthritis, and cancer. Emerging evidence indicates that the gut microbiota affects the response to anticancer therapies by modulating the host immune system. Recent studies have explained a high correlation between the gut microbiota and breast cancer: dysbiosis in breast cancer may regulate the systemic inflammatory response, hormone metabolism, immune response, and the tumor microenvironment. Some of the gut bacteria are related to estrogen metabolism, which may increase or decrease the risk of breast cancer by changing the number of hormones. Further, the gut microbiota has been seen to modulate the immune system in respect of its ability to protect against and treat cancers, with a specific focus on hormone receptor-positive breast cancer. Probiotics and other therapies claiming to control the gut microbiome by bacterial means might be useful in the prevention, or even in the treatment, of breast cancer. Conclusions: The present review underlines the various aspects of gut microbiota in breast cancer risk and its clinical application, warranting research on individualized microbiome-modulated therapeutic approaches to breast cancer treatment.

29 March 2025 in Life
Verified
Journal Article
Open access
PDF file
RAReema Almotairi
Reema Almotairi
RMRashid Mir
Rashid Mir
KAKholoud S. Almasoudi
Kholoud S. Almasoudi
EHEram Mukhtar Husain
Eram Mukhtar Husain
NMNabil Mtiraoui
Nabil Mtiraoui
Background: As a complicated endocrine condition, polycystic ovarian syndrome affects around 20% of women who are of reproductive age. It is linked to an increased risk of endometrial cancer, cardiovascular diseases, mental illnesses, non-alcoholic fatty liver disease, metabolic syndrome, and Type 2 diabetes. Despite numerous genetic studies identifying several susceptibility loci, these only account for approximately 10% of the hereditary factors contributing to PCOS, leaving its etiology largely unknown. While genome-wide association studies (GWAS) have been conducted on various populations to identify SNPs linked to PCOS risk, no such study has been reported in Tabuk. Thus, this study aims to investigate the association of a glutathione S-transferase M1 (GSTM1) deletion, VEGF gene (I/D) insertion/deletion, and VEGF-2578 gene polymorphism with polycystic ovarian syndrome. Methodology: In this research study (case-control), we utilized the ARMS-PCR to determine and analyze the polymorphic variants of VEGF-2578 C/A (rs699947). We employed multiplex PCR for the GSTM1 deletion and MS-PCR (mutation specific PCR) for the vascular endothelial growth factor gene insertion/deletion. Results: The findings indicated statistically significant differences in various biochemical and endocrine serum biomarkers, including lipid profiles (cholesterol, HDL, and LDL), Type 2 diabetes markers (HOMA-IR (Homeostatic Model Assessment for Insulin Resistance), free insulin fasting glucose), and hormone levels (testosterone, LH, progesterone and FSH) in PCOS patients. Specifically, regarding the GSTT1 genotype, individuals with the GSTT1-null genotype had an odds ratio (OR) of 4.16 and a relative risk (RR) of 2.14 compared to those with the GSTT1 genotype, with statistically significant differences (p = 0.0001). However, for the GSTM1 genotype, there was a statistically significant difference (p = 0.0002) in the OR and RR for the GSTM1-null genotype, which were 2.66 and 1.64, respectively. Protective effects were observed for individuals with either GSTT1 (+) GSTM1 (−) or GSTT1 (−) GSTM1 (+) genotypes, as well as for those with both null genotypes, yielding an OR of 0.41 and p < 0.003. The VEGF rs699947 C>A gene variation showed a statistically significant association between PCOS patients and controls (p < 0.020), with the A allele frequency higher among PCOS patients (0.42 vs. 0.30). Similarly, the VEGF rs4646994 I>D gene variation exhibited a statistically significant difference (p < 0.0034), with the D allele being more frequent in PCOS patients (0.52 vs. 0.35). The VEGF-A allele was strongly linked to PCOS susceptibility in the allelic model, exhibiting an OR of 1.62, RR of 1.27, and p < 0.007, while in the allelic comparison, the OR was 1.71, the RR was 1.32, and p < 0.004. Conclusions: This study concluded that null genotypes at rs4025935 and rs71748309, an insertion deletion at rs4646994, and the A allele of rs699947 were significantly associated with PCOS predisposition in our population and these could serve as potential loci for PCOS predisposition. To the best of our knowledge, it is the first study to highlight the association between these genetic variations and the predisposition of PCOS in our populations. Large-scale case-control studies in the future are required to confirm these results.

28 July 2024 in Life
Verified
Journal Article
Open access
PDF file
KAKholoud S. Almasoudi
Kholoud S. Almasoudi
EHEram Mukhtar Husain
Eram Mukhtar Husain
RAReema Almotairi
Reema Almotairi
TBTanzeela Bhat
Tanzeela Bhat
NMNabil Mtiraoui
Nabil Mtiraoui
RMRashid Mir
Rashid Mir
PCOS is a heterogeneous, multifactorial endocrine disorder with a complex pathophysiology. It is a globally rising infertility disorder that affects a large percentage of women of reproductive age, with a relatively high prevalence of 8–13%. Genome-wide association studies have revealed associations of genetic variations with many diseases, including PCOS. The cellular activity of IL8 is mediated by the receptor CXCR2, and transcription of IL8 is controlled by TNF-α. Therefore, this study aimed to investigate the association of TNF-α, CCR5-delta32, and CXCR2 gene variations with PCOS. Methodology: In this case control study, we used amplification-refractory mutation system (ARMS)-PCR to detect and determine the presence of the polymorphic variants TNF-α, CCR5-delta32, and CXCR2 in the study subjects. These gene polymorphs may serve as critical candidate gene variants in PCOS pathogenesis and therapeutics. Results: The case–control study’s findings revealed that the majority of the biochemical and endocrine serum biomarkers examined in the investigation—including lipids (LDL, HDL, and cholesterol), T2DM markers (fasting glucose, free insulin, and HOMA-IR), and hormones (FSH, LH, testosterone, and progesterone)—exhibited statistically significant changes in PCOS patients. The distributions of TNF-α (rs1800629), CCR5-delta32, and CXCR2 (rs2230054) genotypes analyzed within PCOS patients and healthy controls in the considered population were significant (p < 0.05). The heterozygosity of CXCR2-CA, TNF-α GA, and CCR5(WT+Δ32*) genotypes was significantly associated with PCOS susceptibility, with high OR and p < 0.05 in the codominant model. Similarly, the A allele of the TNF-α and CXCR2 genes, along with the CCR5Δ32*(mutant) allele, was significantly associated with PCOS susceptibility, with high OR and p < 0.05. Likewise, the CXCR2 (CA+AA) vs CC genotype was associated with increased susceptibility to PCOS, with OR 2.25, p < 0.032. Conclusions: Our study concludes that TNF-α rs1800629G>A, CXCR2-rs2230054C>T, and CCR5-Delta32 rs333 are potential loci for developing PCOS in the Tabuk population. These findings might eventually be useful in identifying and classifying those who are at risk for PCOS. To validate these results, it is advised that further longitudinal studies be conducted in diverse ethnic populations and with larger sample sizes.

18 October 2026 in Diseases
Verified
Journal Article
Open access
PDF file
RMRashid Mir
Rashid Mir
NANaseh Algehainy
Naseh Algehainy
MJMohammed M Jalal
Mohammed M Jalal
MAMalik Altayar
Malik Altayar
RAReema Almotairi
Reema Almotairi
EHEram Mukhtar Husain
Eram Mukhtar Husain
Multiple sclerosis (MS) has shifted in a generation from an uncommon diagnosis in Saudi Arabia to a major cause of neurological disability in young adults. Available Saudi data describe clinical characteristics broadly similar to those reported elsewhere in the Middle East and do not show that Saudi patients differ from trial populations, although this does not establish equivalent efficacy or safety. How far global advances are usable in the Kingdom has not, however, been synthesized. This narrative review maps diagnostic and therapeutic strategies across five separately reported domains (clinical evidence, 2022 national consensus listing, affordability, monitoring requirement, regional data), with categories assigned by a pre-specified rule, not a composite grade. Regional evidence on established therapies is entirely observational: cohorts report favourable outcomes with fingolimod, natalizumab, and off-label rituximab but cannot establish comparative effectiveness, and physicians report cost, availability, and insurance formularies as constraints whose extent has not been quantified. Diagnosis, now based on the 2024 McDonald revision, is transferable in knowledge but depends on AQP4-IgG testing, MRI, and biomarker capacity whose national distribution is undocumented, with neuromyelitis optica spectrum disorder an important differential. Tolebrutinib, recently approved in Europe for non-relapsing secondary progressive MS, and experimental modalities remain regulatory or research questions without regional data. Saudi studies document substantial payer costs of disease-modifying therapy, but none have measured how often cost or infrastructure alters treatment; we propose a prioritized research agenda.